Secretory Transport of Ranitidine and Famotidine across Caco-2 Cell Monolayers
- Division of Drug Delivery and Disposition, School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- Dr. Dhiren R. Thakker, Division of Drug Delivery and Disposition, School of Pharmacy, CB no. 7360, Beard Hall, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail:dhiren_thakker{at}unc.edu
Abstract
The secretory transport of the H2-antagonists, ranitidine and famotidine, across Caco-2 cell monolayers was found to be a saturable process. Both drugs exhibited greater permeability in the basolateral (BL) to apical (AP) direction than in the AP to BL direction, indicating apically directed secretion; BL to AP transport was inhibited by P-glycoprotein (P-gp) inhibitors verapamil and cyclosporin A. The cellular uptake of ranitidine across the BL membrane was saturable and temperature dependent, indicative of carrier-mediated transport. The Km andVmax for the uptake process were estimated to be 66.9 mM and 20.9 nmol/mg of protein/min, respectively. The uptake of [14C]ranitidine across the BL membrane was inhibited by unlabeled ranitidine and structurally diverse organic cations. The tetraethylammonium (TEA)-sensitive organic cation transporters are not involved in the uptake of ranitidine and famotidine across the BL membrane of Caco-2. This conclusion was based on the evidence that functionally active TEA-sensitive organic cation transporters did not exist in the BL membranes of the Caco-2 cells, whereas the functionally active TEA-sensitive organic cation transporter(s) in LLC-PK1 cells did not contribute to the transport of ranitidine or famotidine across the cell monolayers. Thus, we conclude that the secretory transport of ranitidine and famotidine across Caco-2 cell monolayers is mediated by 1) a carrier in the BL membrane that is distinct from the TEA-sensitive organic cation transporter(s) and 2) P-gp in the apical membrane.
Footnotes
-
DOI: 10.1124/jpet.102.038521
- Abbreviations:
- P-gp
- P-glycoprotein
- AP
- apical
- BL
- basolateral
- CsA
- cyclosporin A
- 2,4-DNP
- 2,4-dinitrophenol
- OCT
- organic cation transporter
- MPP+
- 1-methyl-4-phenylpyridinium
-
- Received May 9, 2002.
- Accepted July 8, 2002.
- The American Society for Pharmacology and Experimental Therapeutics



